Introduction {#Sec1}
============

Leukocyte immunoglobulin (Ig)-like receptors (LILR; also termed LIR or ILT) are mainly expressed on the surface of myelomonocytic cells (Brown et al. [@CR5]) and they have been shown to be important mediators of immunological tolerance (Manavalan et al. [@CR25]; Kim-Schulze et al. [@CR20]). They have been proposed to regulate the function of Toll-like receptors (TLR) and to alter the phenotype and profile of cytokine production by antigen presenting cells (Chang et al. [@CR8], [@CR9]; Anderson and Allen [@CR1]; Brown et al. [@CR6]), thereby controlling both innate and adaptive immune responses. Their functions have been linked to control of bacterial and viral infection (Brown et al. [@CR6]; Lee et al. [@CR23]; Pilsbury et al. [@CR30]). LILRs are genetically associated with autoimmune diseases such as multiple sclerosis (Koch et al. [@CR21]; Ordóñez et al. [@CR28]), Sjögren\'s syndrome (Kabalak et al. [@CR19]), and rheumatoid arthritis (Kuroki et al. [@CR22]; Huynh et al. [@CR14]).

LILR receptors can be classified into two main groups, LILRA and LILRB. The LILRA group includes genes that have truncated cytoplasmic tails and associate with the γ-chain of FcεRI through a charged arginine residue in the transmembrane domain, delivering an activating signal through an immunoreceptor tyrosine-based activation motif (ITAM) (Nakajima et al. [@CR26]). One exception is LILRA3, a soluble protein that has no known signalling ability (Borges et al. [@CR4]; Colonna et al. [@CR12]). On the other hand, LILRB proteins have long cytoplasmic tails with immunoreceptor tyrosine-based inhibitory motifs (ITIM). Some LILR receptors interact with HLA class I (Group 1: LILRB1, -B2, -A1, -A2 and -A3) and they share significant amino acid sequence homology over class I-binding regions (Borges et al. [@CR4]; Colonna et al. [@CR11]; Fanger et al. [@CR13]; Willcox et al. [@CR38]). The ligands for the other receptors, including LILRB3-B5 and LILRA5-A6 are unknown, except for LILRA4 which binds CD317 (Cao et al. [@CR7]; Tavano et al. [@CR34]). These receptors contain non-conservative substitutions in class I binding regions identified in group 1(Willcox et al. [@CR38]).

*LILR* are encoded within the leukocyte receptor complex (LRC) on chromosome 19q13.4 (Fig. [1](#Fig1){ref-type="fig"}), adjacent to the related killer immunoglobulin (Ig)-like receptor (KIR) genes (Barrow and Trowsdale [@CR2]). KIR genes exhibit considerable sequence polymorphism (Robinson et al. [@CR31]) and extensive copy number variation (CNV) (Jiang et al. [@CR16]). LILRB3 and LILRA6 are paired receptors which potentially deliver opposing signals. The genes encoding these receptors display remarkable diversity within their extracellular domains when compared to either *LILRB1* or *LILRB2* (Colonna et al. [@CR10]). For example, there is evidence for variation in the number of copies of *LILRA6* (Sudmant et al. [@CR33]). In addition, it has been reported that some individuals lack *LILRA3* gene expression as a consequence of a large deletion of 6.7 kbp, resulting in the removal of four Ig domain and two leader peptide exons from the genomic sequence (Torkar et al. [@CR35]).Fig. 1*LILR* genes. The LILR family is located in the LRC on chromosome 19q13.4 neighbouring the KIR family of genes. It is composed of two inverted clusters separated by *LAIR* and other genes. The transcription of each of these *LILR* clusters is in a head to tail fashion, as indicated by the *arrows*

To gain insight into the genetics and functions of the polymorphic *LILR* that do not bind class I, we characterised variation in *LILRB3* and *LILRA6* genes and examined them for CNV.

Materials and methods {#Sec2}
=====================

Samples {#Sec3}
-------

Sequencing analysis was performed in cDNA samples from 20 healthy individuals from the Cambridge Blood Centre. Informed consent was obtained from all individuals. CNV assay was carried out in DNA samples from 48 human cell lines from the International Histocompatibility Working Group from different ethnic origins (see Table [S1](#MOESM1){ref-type="media"}).

Sequencing {#Sec4}
----------

RNA extraction and subsequent cDNA synthesis was performed as described previously (Jones et al. [@CR18]). Transcripts were initially amplified from macrophage cDNA using primers NK1078 and NK1091 for *LILRB3* (see Table [S2](#MOESM2){ref-type="media"} for primer details) and, NK1078 and NK636 for *LILRA6*. These initial polymerase chain reactions (PCRs) were performed using Phusion polymerase (Finnzymes) with the following cycling parameters: 30 s at 98 °C followed by 35 cycles of 98 °C for 10 s, 68 °C for 30 s, and 72 °C for 60 s. All PCRs were performed on the MJ Research (Reno, NV, USA) PTC-200 thermal cycler. Products were assessed by cycle sequencing using BigDye Terminator version 3.1 methodology (Applied Biosystems) and an Applied Biosystems 3730xl DNA analyser using the primers NK1078 and NK1495 (*LILRB3*), or NK1078, NK1404 and NK1494 (*LILRA6*) (Table [S2](#MOESM2){ref-type="media"}).

To determine the sequences of single alleles within heterozygote individuals, we performed PCRs on individual cDNAs, using forward primers with specificity for single nucleotide polymorphisms (SNPs) (Table [S2](#MOESM2){ref-type="media"}). These SNP-specific primers (SSP) were used in conjunction with either the *LILRB3*-specific reverse primer NK1091 or the *LILRA6*-specific NK636. The cycling conditions were: 180 s at 96 °C, followed by 5 cycles of 96 °C for 20 s, 70 °C for 45 s, and 72 °C for 25 s. This was followed by 31 cycles of 96 °C for 25 s, 65 °C for 50 s and 72 °C for 30 s; followed by 4 cycles of 96 °C for 30 s, 55 °C for 60 s and 72 °C for 90 s. All amplicons from PCR-SSP carried an M13R tag at the 5′ end, which was exploited for subsequent cycle sequencing using the primers M13R, in addition to NK1495, NK1404 and NK1494.

Sequence analysis: calculation of dN/dS ratios and statistical tests {#Sec5}
--------------------------------------------------------------------

To assess putative evolutionary selection pressure on polymorphism acting on the extracellular immunoglobulin-like region of *LILRB3* and *LILRA6* alleles, non-synonymous (dN) and synonymous (dS) substitution rates for all pairwise comparisons of alleles from both loci were calculated using the KaKs Calculator (Zhang et al. [@CR43]), applying Nei and Gojobori\'s method and incorporating Jukes--Cantor correction (Nei and Gojobori [@CR27]).

One-tailed Fisher\'s exact tests for positive selection for sequence pairs were performed on the entire extracellular Ig region of *LILRB3* and *LILRA6* using Graphpad (<http://www.graphpad.com/quickcalcs/>) as previously described (Zhang et al. [@CR42]). Results were considered statistically significant with *p* \< 0.05.

Quantitative PCR {#Sec6}
----------------

*LILR* copy number was determined by quantitative PCR (qPCR), on genomic DNA extracted from 48 human cell lines from the International Histocompatibility Working Group (<http://www.ihwg.org/hla/>) using the QIAamp DNA Blood Midi Kit (QIAGEN) following the manufacturer\'s instructions. The following genes were typed for CNV: *LILRA1*, *LILRA2*, *LILRA3*, *LILRA4*, *LILRA5*, *LILRA6*, *LILRB1*, *LILRB2*, *LILRB3*, *LILRB4* and *LILRB5*.

Forward and reverse primers, and a dual-labelled probe were designed to specifically amplify each LILR gene (Table [S3](#MOESM3){ref-type="media"}), avoiding any allelic variation identified to date. *LILR* sequences were analysed for specificity using the primerBLAST tool from the National Centre for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/tools/primer-blast>). In addition, all reactions contained specific primers and a probe for the *STAT6* gene, which has two copies per diploid human genome, and was used as an endogenous reference gene. All reactions were performed in quadruplicate for each sample to increase the accuracy of copy number scoring.

A total of 10 ng of genomic DNA was amplified under the following PCR conditions: 5 min at 95 °C; followed by 40 cycles of 95 °C for 15 s and 66 °C for 50s; followed by 10s at 40 °C, using the LightCycler 480 System (Roche Diagnostics Ltd., Burgess Hill, UK). *LILR* copy number was determined by a quantitative PCR comparative Ct method (Schmittgen and Livak [@CR32]).

SSP-PCR genotyping {#Sec7}
------------------

Genotyping for presence of the SNP that encodes a threonine (T) at residue 94 within *LILRA6* was performed on genomic DNA samples using the primer pair NK1513 (5′-CCCCCTGGAGCTGGTGAC-3′) and NK559 (5′-TCATCAGAACAAAATGGTGATATCT-3′) or NK560 (5′-CATCAGAACAAAATGGTGATATCC-3′). Detection of a 570-bp deletion located within the intergenic region between *LILRA6* and *LILRB3* was performed using the primer pair NK1520 (5′-CTGGTCCCTGCAGTGGCA-3′) and NK1518 (5′- GCCTTAGACTTCCTATCCTGAAAC-3′). PCR cycling conditions were as previously described (Jones et al. [@CR17]).

Results {#Sec8}
=======

*LILRB3* and *LILRA6* immunoglobulin-like domains are highly polymorphic {#Sec9}
------------------------------------------------------------------------

By exploiting polymorphic sites and unique regions within the 3′ ends of *LILRB3* and *LILRA6*, we were able to characterise the sequences encoding the Ig domains of single alleles. This approach made it possible to identify individual allele sequences regardless of any variation in copy number (see later).

Analysis of the extracellular Ig domain-coding regions of the *LILRB3* and *LILRA6* genes, using cDNA samples from 20 healthy individuals, identified substantial variation in the nucleotide sequences of both receptors (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). This analysis generated 25 different sequences, 21 of which were novel and have subsequently been deposited in Genbank with accession numbers from KF294233 to KF294253.Table 1Predicted amino acids substitutions within the extracellular Ig region of *LILRB3* and *LILRA*6 allelesAlleleIg 1Ig 2Ig 3Ig 4Freq30363846656792949799120126128142152164178182225229265267291294295300318325326327377382386394LILRB301LRDLMELMFNRGHRGNMQDDPHNMADVWWQYHFM0.302------------------------------------V------------------------------0.203----------------------------------R--------------------------------0.1504------------------------------------------N------------------------0.105Q--H------M--AS--------R--TW--N--N----------------R--HV0.0506Q--H------M--AS--------R--TW--N--N------------------------0.0507----------------------------------------------------------------H--0.0508--------------------------------------------------G----------------0.0509----------------------------------------R--------------------------0.3510--Q------Q----AS--R----------R------N----------------RYHV0.1511--Q------Q----AS----DQ--T------H--N----------------------V0.0512--Q--W--Q------------------TTW----RYDIT--MRGYR------0.3513------W--Q------------------TTW----RYDIT--MRGYR------0.0514--Q--W--Q--------------------TW----RYDIT--MRGYR------0.05LILRA601------WI------ASQ------------R--------------------------------0.7502--Q------Q----AS--R----------R------------------------L------0.0503--Q------Q--T--------------TTR------------------RGY--------0.3504--Q------Q------------------TTR------------------RGY--------0.305--Q------Q------------------T----------------------RGY--------0.0506--Q--W--Q------------------TTW------------------RGYR--H--0.107--Q--W--Q------------------TTW----RY----------RGYR--H--0.108--Q--W--Q------------------TTW----RY----------RGY--------0.0509--Q--W--Q------------------TTR----RY----------RGYR--H--0.0510--Q--W--Q--------------------TR----RYDIT--MRGY--------0.0511--Q--W--Q------------------T--R----RYDIT--MRGY-------0.05Residues are numbered in relation to the predicted mature protein sequence. The phenotype frequency of each allele is provided in the final column (*n* = 20 individuals). *Ig* immunoglobulin domainTable 2Synonymous polymorphism within the extracellular Ig-coding region of *LILRB3* and *LILRA6* allelesIg 1Ig 2Ig 3Ig 470(A)98(Y)267(H/N/Y)^a^274(Y)287(S)326(G)^a^392(E)AlleleGC[G]{.ul}TA[C]{.ul}H: CA[C]{.ul}TA[T]{.ul}AG[C]{.ul}G: GG[G]{.ul}GA[A]{.ul}LILRB301- - \-- - -H: - - \-- - \-- - -W- - -01- - \-- - -H: - - \-- - \-- - -W- - -03- - \-- - -H: - - \-- - \-- - -W- - -04- - \-- - -N: A - T- - \-- - -W- - -05- - A- - -N: A - T- - C- - -W- - G06- - A- - -N: A - T- - C- - -W- - -07- - \-- - -H: - - \-- - \-- - -W- - -08- - \-- - -H: - - \-- - \-- - -W- - -09- - \-- - -H: - - \-- - \-- - -W- - -10- - A- - TN: A - T- - C- - -W- - G11- - A- - -N: A - T- - \-- - -W- - G12- - A- - -Y: T - \-- - \-- - TG: - - \-- - -13- - A- - -Y: T - \-- - \-- - TG: - - \-- - -14- - A- - -Y: T - \-- - \-- - TG: - - \-- - -LILRA601- - \-- - TH: - - \-- - \-- - -W- - -02- - A- - TH: - - \-- - \-- - -W- - -03- - A- - -H: - - \-- - \-- - -G: - - T- - -04- - A- - -H: - - \-- - \-- - -G: - - T- - -05- - A- - -H: - - \-- - \-- - -G: - - T- - -06- - A- - -H: - - \-- - \-- - -G: - - T- - G07- - A- - -Y: T - \-- - \-- - -G: - - T- - G08- - A- - -Y: T - \-- - \-- - -G: - - T- - -09- - A- - -Y: T - \-- - \-- - -G: - - T- - G10- - A- - -Y: T - \-- - \-- - -G: - - \-- - -11- - A- - -Y: T - \-- - \-- - -G: - - \-- - -Residue number, amino acid and codon sequences are displayed (residues are numbered in relation to the predicted mature protein sequence). In all cases, synonymous polymorphism occurs at the third position within each codon (*underlined*)^a^Sites where both synonymous and non-synonymous polymorphisms occur in conjunction

We elucidated a total of 41 variable nucleotides in *LILRB3* and *LILRA6* sequences. Twenty-one of the non-synonymous and three of the synonymous substitutions affected the same nucleotide position in the coding sequence of both genes. None of these polymorphisms displayed significant linkage disequilibrium between *LILRB3* and *LILRA6* alleles (data not shown). The inhibitory receptor *LILRB3* encompassed 40 polymorphic sites with 34 non-synonymous and six synonymous substitutions. The activating receptor *LILRA6* showed less variation; 29 polymorphic sites, of which 25 were non-synonymous and four synonymous substitutions (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Moreover, the analysis of these cDNA sequences revealed that four individuals carried three alleles of *LILRA6*, of which *LILRA6\*01* and *\*03* were common to all the samples and in three out of the four samples, the third allele was *LILRA6\*04. LILRA6\*03* was present in the cDNA samples of all individuals with three alleles and it was the only *LILRA6* allele with the SNP 94 T (Table [1](#Tab1){ref-type="table"}), suggesting that this SNP correlated with the increase in the number of copies of *LILRA6*. We performed SSP-PCR to detect the polymorphism at position 94 in the genomic DNA samples from cell lines but did not find any association between the presence of T at position 94 and the increase in the number of copies of *LILRA6* in our cohort (Table [3](#Tab3){ref-type="table"}).Table 3*LILRA6* CNV and presence of tandem repeat sequence and SNP 94 TCell lineCNTRS94 TCell lineCNTRS94 TKT122.89DeletionNegativeRSH3.32DeletionNegativeTAB0892.06CompleteNegativeTL3.04DeletionPositiveXL1-ND2.31CompleteNegativePAR2.06CompleteNegativeRML3.02DeletionNegativeWT243.19DeletionPositiveKY1.68CompleteNegativeSA2.10CompletePositiveHOM21.76CompleteNegativeLATIF1.86CompleteNegativeKT172.01DeletionNegativeOZB1.05CompleteNegativeJESTHOM1.98CompleteNegativeAMAI2.84CompletePositiveAKIBA1.92CompleteNegativeCOX1.96CompletePositiveWWPAK1.90CompleteNegativeKAS0110.38CompleteNegativeGRC3.28DeletionNegativeCO472.11DeletionPositiveBM92.27CompleteNegativeFPAF1.97DeletionNegativeSLE0052.10DeletionPositiveSNA BLL2.01CompleteNegativeDUCAF3.09DeletionNegativeDUGE2.98DeletionNegativePMH 1612.00CompleteNegativeWJR0761.93CompleteNegativeLB1.95CompleteNegativeVAVY2.01CompleteNegativeBTB1.96DeletionNegativeHOR1.10CompleteNegativeIBW93.09DeletionPositiveMANIKA3.89DeletionPositiveDKB3.13DeletionPositiveMGAR2.32DeletionNegativeDEM3.08DeletionPositiveH01041.84DeletionNegativeLBF2.90DeletionPositiveM72.70DeletionNegativeBOLETH1.16CompleteNegativeLCL 7212.13CompletePositiveHO3012.01DeletionPositiveCRGE2.04CompleteNegative317083.75DeletionNegativeMCF1.99DeletionPositive*CN* calculated copy number, *TRS* tandem repeat sequence

Protein evolution by selective pressure can be measured by considering the replacement of nucleotides within codons and by analysing site-by-site the dN/dS substitution ratio between sequences (Yang et al. [@CR41]). This analysis can reveal the presence of either strictly conserved (dN/dS \<1) or rapidly evolving regions in genes (dN/dS \>1). *LILRB3* and *LILRA6* sequences displayed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} were analysed in this manner. There were predominantly non-synonymous polymorphisms, so the dN/dS ratios were consistent with positive selection (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2dN/dS ratios of the extracellular regions of *LILRB3* and *LILRA6* indicate positive selection. **a** dN and dS values from allelic pairwise comparisons of each gene, *LILRB3* (*circles*) and *LILRA6* (*squares*), and inter-gene comparison (*triangles*). Only sequences detected in this study were included in the analysis. The *central plot line* represents balancing selection (where dN = dS). *Shaded symbols* indicate significance using a Fisher\'s exact test for positive selection pressure (Zhang et al. [@CR42]). **b** dN and dS values for previously reported *LILRB1* (*circles*) and *LILRB2* (*squares*) sequences deposited in Genbank (<http://www.ncbi.nlm.nih.gov/genbank/>)

*LILRA3 and LILRA6* genes, but not *LILRB3*, show variation in copy number {#Sec10}
--------------------------------------------------------------------------

We designed assays to detect variation in the number of copies of *LILR* genes by qPCR. CNV was detected in the *LILRA3* and *LILRA6* loci (Fig. [3c](#Fig3){ref-type="fig"} and [f](#Fig3){ref-type="fig"}, respectively). *LILRA3* varied between zero, one or two copies per diploid genome. Around 21 % of the samples lacked *LILRA3*, while \~19 % had only one copy of this gene. CNV in *LILRA6* varied between one, two, three and four copies per diploid genome; \~8 % of the samples had a single copy of the gene, whilst \~33 % carried a duplication of *LILRA6* (three or four copies). Despite its high rate of allelic variation, *LILRB3* had a constant number of two copies per genotype (Fig. [4c](#Fig4){ref-type="fig"}).Fig. 3Copy number variation of activating *LILR* receptor genes. Summaries of the results of copy number assays for *LILRA1* (**a**), *LILRA2* (**b**), *LILRA3* (**c**), *LILRA4* (**d**), *LILRA5* (**e**) and *LILRA6* (**f**). The number of copies per genome was constant (two copies) in activating LILR receptors with the exception of *LILRA3* and *LILRA6,* which displayed variation. *LILRA3* showed from zero to two copies per genome. *LILRA6* showed from one to four copies per genome. Each bar represents the calculated copy number obtained for one sample (see Table [S1](#MOESM1){ref-type="media"}). Number inside plot is the predicted copy number for samplesFig. 4Copy number variation of inhibitory *LILR* receptor genes. Copy number variation was analysed for the inhibitory receptor genes *LILRB1* (**a**), *LILRB2* (**b**), *LILRB3* (**c**), *LILRB4* (**d**) and *LILRB5* (**e**). The figure shows the results of this analysis where each of these receptor genes are present in two copies per genotype. Each bar represents the calculated copy number obtained for one sample (see Table [S1](#MOESM1){ref-type="media"})

We identified a fosmid sequence deposited in Genbank (accession number: AC236241) that contains two sequences of *LILRA6*, the arrangement of which is represented in Fig. [5](#Fig5){ref-type="fig"}. The additional *LILRA6* locus (*LILRA6* \[2\]) occurred \~15 kb upstream of the common *LILRA6* locus (*LILRA6* \[1\]) within the region normally occupied by *LILRB3*. Sequence AC236241 also possesses a deletion within a tandem repeat sequence that is normally located within the intergenic region between *LILRA6* and *LILRB3*. We used the Tandem repeats finder program (Benson [@CR3]) to detect the 33-bp tandem repeat sequence, which has a consensus sequence of TCTATTGAGATCCTATGGAGGTCCTGTGGGGGT and a copy number of 19.9. This repeat was absent from AC236241. By utilising PCR primers that flank this deletion (Fig. [5b](#Fig5){ref-type="fig"}), we found that its presence correlated strongly with the duplication of *LILRA6* within our cohort, occurring in around 93 % of the samples with more than two copies of *LILRA6* (Table [3](#Tab3){ref-type="table"}), indicating that fosmid AC236241 represents a commonly occurring haplotype that carries a duplication of *LILRA6*.Fig. 5Genetic organisation of the centromeric region of the *LILR* gene cluster encompassing *LILRB5*, *LILRB3* and *LILRA6.* **a** Genes are arranged according to their positions as determined by analysis of the representative sequence CU151838 (i) and within fosmid AC236241 (ii). Sequence AC236241 carries two copies of *LILRA6* (labelled *1* and *2*) and a 570-bp deletion within the tandem repeat region present in CU151838. The comparative homology between these two sequences is also presented. Regions occurring within both *LILRB3* and *LILRA6* that share \>95 % identity are indicated, together with the locations of *LILRA6*-specific sequence within AC236241. The AC236241 sequence terminates within the 3′ region of *LILRA6* (2). **b** PCR-based detection of the deleted region identified within fosmid AC236241. Amplification of the tandem repeat sequence between *LILRB3* and *LILRA6* (918 bp) or two *LILRA6* sequences (348 bp). Samples are DEM (*1*), DUCAF (*2*), HOR (*3*), and SA (*4*). The *arrow* indicates the direction of DNA migration. Refer to Table [3](#Tab3){ref-type="table"} for information about the results of *LILRA6* copy number, the deletion within the tandem repeat sequence and results for the SNP 94 T by SSP-PCR

No other *LILR* gene shows CNV {#Sec11}
------------------------------

To determine whether the CNV we observed was a more widespread feature of *LILR* genes, we carried out CNV analysis of all other activating and inhibitory *LILR* genes (*LILRA1*, *-A2*, -*A4*, *-A5*, *-B1*, *-B2*, *-B4* and *-B5*). This analysis did not identify any further variation in the number of copies of other *LILR* genes (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}), indicating that CNV is specific to the *LILRA3* and *LILRA6* loci, or rare for other genes.

Discussion {#Sec12}
==========

Amplification and sequencing of *LILRB3* and *LILRA6* cDNA from 20 individuals returned 25 different sequences with 41 polymorphic sites, consistent with these receptors being highly polymorphic in their extracellular domains (Colonna et al. [@CR10]). Most of variable positions were represented in both *LILRB3* and *LILRA6*, including several synonymous substitutions. This indicates the possibility of genetic transfer between these two genes and the additional copies of *LILRA6*. The patchwork nature of the variation is reminiscent of the variation in some MHC class I or class II genes, in which case it may be achieved by allele or gene conversion (Traherne et al. [@CR36]). Several non-synonymous polymorphisms within *LILRB3* and *LILRA6* occur at positions known to form part of the binding sites of Group 1 LILR to MHC class I: 36, 38, 67, 97, 99 and 126 (Willcox et al. [@CR38]; Yang and Bjorkman [@CR40]). Although no specific ligand for both LILRB3 and LILRA6 receptors has yet been identified, it is tempting to speculate that these variations may have functional consequences. Additionally, we found three alleles of *LILRA6* in four cDNA samples, indicating that the duplicated copies of this gene are expressed and are presumably functional. The fact that three out of four samples had the combination of *LILRA6\*03* and *LILRA6\*04* concurs with the duplication of *LILRA6* found in a fosmid (accession number AC236241). However, this allele pairing was not found in all tri-allelic individuals. Moreover, the SNP 94 T, characteristic of *LILRA6\*03,* which was carried by all four individuals with three alleles, was not associated with the increase in the number of copies of *LILRA6* found in cell lines. Therefore, it would appear that the allele content within the haplotype comprising duplicated *LILRA6* genes is variable.

The method of CNV analysis we describe has a number of advantages: it is simple to carry out, low cost, specific and sensitive and is high-throughput, as up to a thousand samples can be analysed per week. Variation in *LILR* gene copy number was detected within *LILRA3*, which encodes a soluble molecule (Borges et al. [@CR4]; Colonna et al. [@CR12]), and the activating *LILRA6*, while all inhibitory *LILR* genes, including the highly polymorphic *LILRB3*, had a constant number of two copies per diploid genome. The gene frequency of deletion of *LILRA3* was around 40 %, in concordance with previously published results where the frequency of deletions varied from 6 % to 84 % in different populations (Torkar et al. [@CR35]; Wiśniewski et al. [@CR39]). *LILRA6* was more variable; 8.3 % of the samples showed a heterozygous deletion of *LILRA6*, and in 33.3 % of the cases, we observed duplications of this gene (three or four copies).

The variation in the number of copies of *LILRA6* could be due to non-allelic homologous recombination (NAHR) or crossing-over between sequences that are not in allelic positions, a phenomenon proposed for CNV in *KIR* (Traherne et al. [@CR37])*.* These events are mediated by genomic structures that are flanked by paralogous repeat sequences, low-copy repeats, segmental duplications or tandem repeat regions (Jeffreys et al. [@CR15]; Liu et al. [@CR24]). We found a tandem repeat sequence between *LILRB3* and *LILRA6* genes (Fig. [5a](#Fig5){ref-type="fig"}), that was deleted in sequence contained in fosmid AC236241, which carries a duplication of *LILRA6*. Therefore, it could be hypothesised the deletion within the tandem repeat region may be mechanistically linked to the duplication event of *LILRA6* within this haplotype. From analysis of the AC236241 sequence an obvious insertion point of the duplicated *LILRA6* gene could not be identified indicating that unequal crossover could have occurred within the \~4.9-kb homologous region that *LILRA6* shares with *LILRB3* (Fig. [5a](#Fig5){ref-type="fig"}). Recombination centred upon the repeat region may account for the lack of significant linkage disequilibrium observed between alleles of *LILRB3* and *LILRA6*, as determined by the analysis of cDNA from 20 individuals (data not shown).

Our CNV screen indicates that *LILRA6* is absent on some haplotypes. There are two sequences in Genbank (accession numbers: AC235034 and AC153469) that lack *LILRA6*, and instead carry *LILRB3* at that genomic location. The *LILRB3* allele within AC235034 encodes a predicted protein sequence that is identical to *LILRA6\*01* throughout its extracellular region, while the predicted protein encoded by AC153469 only differs with *LILRA6\*01* due to the presence of 164 T. *LILRA6\*01* is the most frequently occurring allele according to our cDNA screen (Table [1](#Tab1){ref-type="table"}) and carries two unique SNPs (65 I and 120 Q), and a unique combination of variable positions 36 R, 46 W and 67 E. We did not detect these polymorphic features within any *LILRB3* allele, suggesting that they are predominately a characteristic of *LILRA6*. Their presence within the *LILRB3* sequences of AC153469 and AC235034 is evidence of an unequal crossover event that has occurred within the homologous region following the Ig2-encoding exon of *LILRA6*, resulting in the replacement of *LILRA6*-specific sequence within the 3′ of the gene with that of *LILRB3*. This indicates that unequal crossover is a mechanism by which genetic information may be exchanged between these two genes (Fig. [6a](#Fig6){ref-type="fig"}). An additional possibility could be the formation of single-stranded DNA (ssDNA) secondary structures or hairpin loops in the repeat tandem sequence (Fig. [6b](#Fig6){ref-type="fig"}). These structures are accessible substrates for nucleases, making them susceptible to strand breaks. This may lead to repair processes that can cause deletion of regions or genetic transfer of homologous sequences between chromosomes. Such recombination processes have previously been proposed in the evolution of the KIR gene cluster (Traherne et al. [@CR37]).Fig. 6Non-allelic homologous recombination and potential ssDNA secondary structures produced at the tandem repeat sequence. **a** The process of unequal crossing-over of homologous sequences proposed to generate deletions (i) or duplications (ii) of *LILRA6*. **b** Seventeen hairpin structures were predicted using the Mfold program (Zuker [@CR44]). Twenty copies of the repeat tandem sequence TCTATTGAGATCCTATGGAGGTCCTGTGGGGGT was used as the input

Functionally, the increase in the number of copies of *LILRA6* could affect the balance between activating and inhibitory signals after ligand binding. How could the combination of CNV and variable sequences be interpreted in terms of function? So far, it is difficult to identify haplotype-specific combinations of variable sequences over the sets of genes, as we do not have sequence information over single haplotypes. If these exist they would be consistent with haplotype-specific interactions with a ligand and integration of signals from the different receptors, as may be the case for some neighbouring KIR A and B haplotypes. They would suggest that the constellations of variable activating and inhibitory receptors on haplotypes are driven by interaction with a variable ligand, such as a variable pathogen.

In conclusion, we have shown high levels of polymorphism and homology between *LILRB3* and *LILRA6* in their extracellular domains, with *LILRA6* also displaying alterations in the number of copies. All the variations observed in these genes may affect ligand binding, the equilibrium between activating and inhibitory signals, and therefore, the balance of immune response. The allelic variation and CNV in the *LILRB3/LILRA6* pair we have described is consistent with strong selection for variation and high dN/dS ratios are characteristic of other immune system genes, such as MHC or KIR, that are involved with resistance to pathogens (Park et al. [@CR29]).
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